Saturday’s Daily Piece: FDA Updates on Insulin Glargine and Metformin ER

FDA has approved insulin glargine (Semglee, U-100) manufactured by Mylan Pharmaceuticals this week. We now have 3 insulin glargine U-100 (Lantus, Basaglar and Semglee) formulations available. Semglee is approved for use in adults and pediatrics with type 1 diabetes and adults with type 2 diabetes.

FDA announces additional companies to being asked to voluntarily recall metformin extended release due to elevated levels of NDMA. Additional details in link below.

https://www.medpagetoday.com/endocrinology/generalendocrinology/87035?xid=nl_mpt_DHE_2020-06-13&eun=g1137305d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202020-06-13&utm_term=NL_Daily_DHE_dual-gmail-definition

Semglee® | Insulin glargine injection|HCP Website
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#FDA #Semglee #metformin #NDMA

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Leave a Reply

Your email address will not be published. Required fields are marked *